MedWorm: Bupropion

Bupropion: Partial status epilepticus: case report

Reactions — Thu, 02 Feb 2012 18:34:27 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUPROPION HYDROCHLORIDEtablet, Film Coated [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 01 Feb 2012 05:00:00 +0100

Updated Date: Feb 1, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Antidepressants and the risk of abnormal bleeding during spinal surgery: a case–control study

European Spine Journal — Tue, 31 Jan 2012 07:05:28 +0100

Conclusion Clinicians treating patients who are planning to undergo elective spinal surgery and are on an antidepressant medication should be aware of this potential effect and should consider tapering off the serotonergic antidepressant prior to surgery. Content Type Journal ArticleCategory Original ArticlePages 1-9DOI 10.1007/s00586-011-2132-8Authors Amirali Sayadipour, Division of Spinal Surgery, Department of Orthopaedic Surgery, The Rothman Institute, Thomas Jefferson University, 925 Chestnut St, 5th floor, Philadelphia, PA 19107, USARajnish Mago, Department of Psychiatry, Thomas Jefferson University, Philadelphia, USAChristopher K. Kepler, Division of Spinal Surgery, Department of Orthopaedic Surgery, The Rothman Institute, Thomas Jefferson University, 925 Ches...

Neuromodulators for pain management in rheumatoid arthritis

NeLM - Drug Class Focused Reviews — Tue, 31 Jan 2012 05:00:00 +0100

Source: Cochrane Library Area: Evidence > Drug Class Focused Reviews Background Pain management is a high priority for patients with rheumatoid arthritis (RA). Despite deficiencies in research data, neuromodulators have gained widespread clinical acceptance as adjuvants in the management of patients with chronic musculoskeletal pain. Objectives The aim of this review was to determine the efficacy and safety of neuromodulators in pain management in patients with RA. Neuromodulators included in this review were anticonvulsants (gabapentin, pregabalin, phenytoin, sodium valproate, lamotrigine, carbamazepine, levetiracetam, oxcarbazepine, tiagabine and topiramate), ketamine, bupropion, methylphenidate, nefopam, capsaicin and the cannabinoids. Search ...

Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes

Human Genetics — Mon, 30 Jan 2012 16:06:58 +0100

Abstract Many smokers attempt to quit smoking but few are successful in the long term. The heritability of nicotine addiction and smoking relapse have been documented, and research is focused on identifying specific genetic influences on the ability to quit smoking and response to specific medications. Research in genetically modified cell lines and mice has identified nicotine acetylcholine receptor subtypes that mediate the pharmacological and behavioral effects of nicotine sensitivity and withdrawal. Human genetic association studies have identified single nucleotide polymorphisms (SNPs) in genes encoding nicotine acetylcholine receptor subunits and nicotine metabolizing enzymes that influence smoking cessation phenotypes. There is initial promising evidence for a role ...

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 27 Jan 2012 05:00:00 +0100

Updated Date: Jan 27, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Neuromodulators for pain management in rheumatoid arthritis.

Cochrane Database of Systematic Reviews — Thu, 26 Jan 2012 08:18:08 +0100

CONCLUSIONS: There is currently weak evidence that oral nefopam, topical capsaicin and oromucosal cannabis are all superior to placebo in reducing pain in patients with RA. However, each agent is associated with a significant side effect profile. The confidence in our estimates is not strong given the difficulties with blinding, the small numbers of participants evaluated and the lack of adverse event data. In some patients, however, even a small degree of pain relief may be considered worthwhile. Until further research is available, given the relatively mild nature of the adverse events, capsaicin could be considered as an add-on therapy for patients with persistent local pain and inadequate response or intolerance to other treatments. Oral nefopam and oromucosal cannabis have more signif...

Interventions for preventing weight gain after smoking cessation.

Cochrane Database of Systematic Reviews — Thu, 26 Jan 2012 08:18:08 +0100

CONCLUSIONS: Although some pharmacotherapies tested to limit PCWG show evidence of short-term success, other problems with them and the lack of data on long-term efficacy limits their use. Weight management education only, is not effective and may reduce abstinence. Personalised weight management support may be effective and not reduce abstinence, but there are too few data to be sure. One study showed a VLCD increased abstinence but did not prevent WG in the longer term. CBT to accept WG did not limit PCWG and may not promote abstinence in the long term. Exercise interventions significantly reduced weight in the long term, but not the short term. More studies are needed to clarify whether this is an effect of treatment or a chance finding. Bupropion, fluoxetine, NRT and varenicline reduce...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Global Pharmaceuticals, Division Of Impax Laboratories, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 26 Jan 2012 05:00:00 +0100

Updated Date: Jan 26, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion/alcohol interaction: Aggressive behaviour: case report

Reactions — Mon, 23 Jan 2012 18:35:21 +0100

(Source: Reactions)

Systematic review of the cost‐effectiveness of varenicline vs. bupropion for smoking cessation

International Journal of Clinical Practice — Sat, 21 Jan 2012 13:59:50 +0100

Conclusions regarding the cost‐effectives were changed upon sensitivity analysis with the following variables: time horizon, cost of bupropion, efficacy of either drug, age and the incidence of smoking related disease. Varenicline dominated bupropion in most cost‐effectiveness models. However, applicability of models to clinical practice and variables which changed conclusion of cost‐effectiveness should be considered in the interpretation of results. (Source: International Journal of Clinical Practice)

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [H.J. Harkins Company, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 20 Jan 2012 05:00:00 +0100

Updated Date: Jan 20, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Treatments for Methamphetamine Abuse: A Literature Review for the Clinician

Journal of Pharmacy Practice — Tue, 17 Jan 2012 05:00:00 +0100

The objective of this article is to critically review the literature of METH treatment options. Preclinical research and human research with compounds not yet available commercially in the United States will not be included. A literature review was conducted for research on pharmacological treatments for METH use and addiction. Trial information on the use of sertraline, bupropion, mirtazapine, modafinil, dextroamphetamine, ondansetron, risperidone, aripiprazole, baclofen, and gabapentin was reviewed. Aripiprazole trials appeared in the reviewed literature more frequently than the other medications. Based on the findings of this review, no single medication demonstrated consistent efficacy and each trial contained a variety of methodological limitations. (Source: Journal of Pharmacy Practi...

Baclofen/bupropion overdose: Various toxicities: case report

Reactions — Fri, 13 Jan 2012 23:22:43 +0100

(Source: Reactions)

Bupropion: Hyperinsulinism (first report) and seizures in a neonate after in utero exposure: case report

Reactions — Fri, 13 Jan 2012 23:22:43 +0100

(Source: Reactions)

Bilateral Uveal Effusion and Angle-Closure Glaucoma Associated With Bupropion Use [Research Letters]

Archives of Opthalmology — Mon, 09 Jan 2012 05:00:00 +0100

(Source: Archives of Opthalmology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Pilot Randomized Clinical Trial of an SSRI vs Bupropion: Effects on Suicidal Behavior, Ideation, and Mood in Major Depression. - Grunebaum MF, Ellis SP, Duan N, Burke AK, Oquendo MA, John Mann J.

SafetyLit: All (Unduplicated) — Fri, 06 Jan 2012 15:21:09 +0100

This study compared a serotonin reuptake inhibitor with a noradrenergic/dopam... (Source: SafetyLit: All (Unduplicated))

Real world evaluation of three models of NHS smoking cessation service in England

BMC Research Notes — Fri, 06 Jan 2012 05:00:00 +0100

Conclusion: The results suggest that service structure, method of support, healthcare professional involved and pharmacotherapy all play a role in a successful quit. Services must be tailored to support individual needs with patient choice and access to varied services being key factors. (Source: BMC Research Notes)

BUPROPION HYDROCHLORIDE EXTENDED RELEASE SR (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 05 Jan 2012 05:00:00 +0100

Updated Date: Jan 5, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Unexpected aggressive behaviour: Interaction of bupropion and alcohol. - Chandler P, Herxheimer A.

SafetyLit: All (Unduplicated) — Sun, 01 Jan 2012 12:07:07 +0100

[Abstract unavailable] Language: Eng... (Source: SafetyLit: All (Unduplicated))

Depression Treatment in Patients With General Medical Conditions: Results From the CO-MED Trial.

Annals of Family Medicine — Sun, 01 Jan 2012 05:00:00 +0100

CONCLUSIONS Patients with general medical conditions can be safely and effectively treated for MDD with antidepressants with no additional adverse effect or tolerability burden relative to their counterparts without such conditions. Combination therapy is not associated with an increased treatment response beyond that found with traditional monotherapy in patients with MDD, regardless of the presence and number of general medical conditions. PMID: 22230827 [PubMed - in process] (Source: Annals of Family Medicine)

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUPROPION HYDROCHLORIDEtablet, Extended Release [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 28 Dec 2011 05:00:00 +0100

Updated Date: Dec 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses

Annals of the Rheumatic Diseases — Wed, 28 Dec 2011 05:00:00 +0100

Conclusions Sympathetic activity mainly increases the severity of acute episodes of immune-mediated arthritis. Therapeutic reduction of sympathetic activity at acute stages attenuates inflammation, hyperalgesia and proinflammatory immune parameters. (Source: Annals of the Rheumatic Diseases)

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 27 Dec 2011 05:00:00 +0100

Updated Date: Dec 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Brief opportunistic smoking cessation interventions: a systematic review and meta‐analysis to compare advice to quit and offer of assistance

Addiction — Fri, 16 Dec 2011 05:00:00 +0100

Conclusions Physicians may be more effective in promoting attempts to stop smoking by offering assistance to all smokers than by advising smokers to quit and only offering assistance to those that express an interest in doing so. (Source: Addiction)

Rates of 5 Common Antidepressant Side Effects Among New Adult and Adolescent Cases of Depression: A Retrospective US Claims Study.

Clinical Therapeutics — Thu, 15 Dec 2011 05:00:00 +0100

CONCLUSIONS: Prevalence and risk of the 5 side effects varied across types of antidepressants for both adults and adolescents. Results from this study were consistent with prior clinical trials, suggesting that variation in side effect profiles exists in a more generalized managed care population. PMID: 22177545 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Influence of Acute Bupropion Pretreatment on the Effects of Intranasal Cocaine

Addiction — Tue, 13 Dec 2011 05:00:00 +0100

Conclusions: The atypical anti‐depressant, bupropion, acutely appears to reduce preference for intranasal cocaine versus a small amount of money but to increase reported positive experiences of the drug. (Source: Addiction)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Actavis South Atlantic LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 13 Dec 2011 05:00:00 +0100

Updated Date: Dec 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE EXTENDED-RELEASE (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Anchen Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 12 Dec 2011 05:00:00 +0100

Updated Date: Dec 12, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE XL (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Lake Erie Medical DBA Quality Care Products LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 07 Dec 2011 05:00:00 +0100

Updated Date: Dec 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Uliginosin B, a phloroglucinol derivative from Hypericum polyanthemum: A promising new molecular pattern for the development of antidepressant drugs.

Behavioural Brain Research — Fri, 02 Dec 2011 05:00:00 +0100

In this study we have demonstrated that cyclohexane extract of Hypericum polyanthemum (POL) and its main phloroglucinol derivative uliginosin B (ULI) present antidepressant-like activity in rodent forced swimming test (FST). The involvement of monoaminergic neurotransmission on the antidepressant-like activity of ULI was evaluated in vivo and in vitro. POL 90mg/kg (p.o.) and ULI 10mg/kg (p.o.) reduced the immobility time in the mice FST without altering locomotion activity in the open-field test. The combination of sub-effective doses of POL (45mg/kg, p.o.) and ULI (5mg/kg, p.o.) with sub-effective doses of imipramine (10mg/kg, p.o.), bupropion (3mg/kg, p.o.) and fluoxetine (15mg/kg, p.o.) induced a significant reduction on immobility time in FST. The pretreatment with SCH 23390 (15μg/kg,...

MedWorm Sponsor Message: Find the best January Sales in the UK.

A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression

Journal of Affective Disorders — Thu, 01 Dec 2011 14:23:58 +0100

Conclusions: These preliminary results seem to support the hypothesis that in patients unresponsive to SSRIs the administration of antidepressants with different mechanisms of action is an effective switching strategy. Further studies are needed in light of the challenge posed by resistant depression. (Source: Journal of Affective Disorders)

The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition

Journal of Psychopharmacology — Thu, 01 Dec 2011 05:00:00 +0100

There is a need for antidepressants with novel mechanisms of action. One approach has been to develop compounds that inhibit reuptake of all three monoamines in the central nervous system, for example DOV216,303. Differential reinforcement of low-rate (72-s) responding is a behavioral test that is predictive of antidepressant-like properties. The effects of antidepressant compounds belonging to multiple classes, the anxiolytic diazepam and the antipsychotic haloperidol, were assessed in the DRL-72s task. Subsequently, the antidepressant-like properties of acute DOV216,303 were assessed. The selective serotonin reuptake inhibitor fluvoxamine, the preferential norepinephrine reuptake inhibitor desipramine and the tricyclic antidepressant imipramine exhibited antidepressant-like properties in...

Bupropion for adults with attention‐deficit hyperactivity disorder: Meta‐analysis of randomized, placebo‐controlled trials

Psychiatry and Clinical Neurosciences — Thu, 01 Dec 2011 05:00:00 +0100

Conclusion: The evidence suggests that bupropion is superior to placebo and effective for the treatment of ADHD in adults. However, its acceptability and tolerability were not significantly higher than those of placebo. (Source: Psychiatry and Clinical Neurosciences)

Forfivo XL (Bupropion Hydrochloride) - updated on RxList

RxList - New and Updated Drug Monographs — Mon, 28 Nov 2011 07:00:00 +0100

Forfivo XL (Bupropion Hydrochloride) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

Antihypertensives/bupropion/insulin/soya oil emulsion: Cardiogenic shock and bradyasystolic arrest: 2 case reports

Reactions — Tue, 22 Nov 2011 06:51:47 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking

BMC Public Health - Latest articles — Mon, 21 Nov 2011 05:00:00 +0100

DiscussionCytisine appears to be effective compared with placebo, and given its (current) relative low cost may be an acceptable smoking cessation treatment for smokers, particularly those in low- and middle-income countries. Cytisine's 'natural' product status may also increase its acceptability and use among certain groups of smokers, such as indigenous people, smokers in countries where the use of natural medicines is widespread (e.g. China, India), and in those people who do not want to use NRT or anti-depressants to help them quit smoking. However it is important to ascertain the effectiveness of cytisine compared with that of existing cessation treatments.Trial registrationAustralian New Zealand Clinical Trials Registry (ACTRN12610000590066) (Source: BMC Public Health - Latest articl...

Why two smoking cessation agents work better than one: Role of craving suppression.

Journal of Consulting and Clinical Psychology — Mon, 21 Nov 2011 05:00:00 +0100

Conclusion: Suppression of craving on the quit day significantly mediates the clinical effects of monotherapies and combination smoking pharmacotherapies, and the higher abstinence rates for combination therapy versus monotherapies appear primarily due to greater craving suppression. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (Source: Journal of Consulting and Clinical Psychology)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 14 Nov 2011 05:00:00 +0100

Updated Date: Nov 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Extended Release [BTA Pharmaceuticals ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 14 Nov 2011 05:00:00 +0100

Updated Date: Nov 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Suicidal behavior and depression in smoking cessation treatments. - Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S.

SafetyLit: All (Unduplicated) — Sun, 13 Nov 2011 23:51:22 +0100

BACKGROUND: Two treatments for smoking cessation-varenicline and bupropion-carry Boxed Warnings from the U.S. Food and Drug Administration (FDA) about suicidal/self-injurious behavior and depression. However, some epidemiological studies report an increase... (Source: SafetyLit: All (Unduplicated))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial

Acta Psychiatrica Scandinavica — Sat, 12 Nov 2011 05:00:00 +0100

Conclusion: In all domains of the pharmacopsychometric triangle, bupropion‐SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram. (Source: Acta Psychiatrica Scandinavica)

High-Dose Bupropion Wins FDA Nod

MedPage Today Psychiatry — Fri, 11 Nov 2011 17:58:27 +0100

(MedPage Today) -- The FDA has approved a new, high-dose formulation of the antidepressant drug bupropion, a pill containing 450 mg of the drug, according to its manufacturer. (Source: MedPage Today Psychiatry)

IntelGenx Announces FDA Approval of Its High Dose Anti-Depressant CPI-300

Medical News (via PRIMEZONE) — Fri, 11 Nov 2011 11:10:00 +0100

SAINT LAURENT, Quebec, Nov. 11, 2011 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) ("IntelGenx") today announced that the U.S. Food and Drug Administration (FDA) has approved IntelGenx' lead product, CPI-300, for patients with Major Depressive Disorder. CPI-300 is a novel, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL. CPI-300 is the only single dose 450 mg formulation of Bupropion HCl approved by the FDA. (Source: Medical News (via PRIMEZONE))

Bupropion: Hyponatraemia: case report

Reactions — Thu, 10 Nov 2011 08:03:53 +0100

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Actavis South Atlantic LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 07 Nov 2011 05:00:00 +0100

Updated Date: Nov 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Does acceptance and relationship focused behavior therapy contribute to bupropion outcomes? A randomized controlled trial of functional analytic psychotherapy and acceptance and commitment therapy for smoking cessation.

Behavior Therapy — Fri, 04 Nov 2011 08:45:57 +0100

This study evaluated a treatment combining bupropion with a novel acceptance and relationship focused behavioral intervention based on the acceptance and relationship context (ARC) model. Three hundred and three smokers from a community sample were randomly assigned to bupropion, a widely used smoking cessation medication, or bupropion plus functional analytic psychotherapy (FAP) and acceptance and commitment therapy (ACT). Objective measures of smoking outcomes and self-report measures of acceptance and relationship processes were taken at pretreatment, posttreatment, 6-month, and 1-year follow-up. The combined treatment was significantly better than bupropion alone at 1-year follow-up with 7-day point prevalence quit rates of 31.6% in the combined condition versus 17.5% in the medication...

Another cessation aid goes up in smoke

Health Facts and Fears — Fri, 04 Nov 2011 04:00:00 +0100

Two drugs used to help people stop smoking — varenicline (Chantix) and bupropion (Zyban) — carry a significantly increased risk of depression and suicidal or self-injurious behavior, according to a new study published in the Public Library of Science. (Source: Health Facts and Fears)

Suicide risk higher with varenicline than other stop-smoking meds

theHeart.org — Thu, 03 Nov 2011 13:15:45 +0100

Chantix should not be a first-line choice for smoking cessation, authors of a new paper say. Their study found significantly more cases of suicidal behavior and depression with varenicline than with bupropion or nicotine replacements. (Source: theHeart.org)

Analysis investigates risks of suicidal behavior and depression with smoking cessation treatments

NeLM - Mental Health — Thu, 03 Nov 2011 04:00:00 +0100

Source: PLoS One Area: News The findings of this American study suggest that varenicline is associated with a significantly increased risk for suicidal behavior and depression. Bupropion, for smoking cessation, was found to be associated with smaller increased risks. The researchers note that both varenicline and bupropion are treatments for smoking cessation and both carry Boxed Warnings from the United States Food and Drug Administration (U.S FDA) relating to suicidal/self-injurious behavior and depression. They examined the comparative neuropsychiatric safety profiles of varenicline and bupropion with regard to suicidal/self-injurious behavior and depression as reflected in adverse drug event data. Data for serious injury case reports between 1998 and September 2010 from the...

Greater Suicide Risk With Varenicline vs Other Cessation MedsGreater Suicide Risk With Varenicline vs Other Cessation Meds

Medscape Today Headlines — Wed, 02 Nov 2011 21:00:18 +0100

A comparison study of smoking cessation medications shows that varenicline was associated with significantly more cases of suicidal behavior and depression than bupropion or nicotine replacement therapy. Medscape Medical News (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials

Neuropsychopharmacology — Wed, 02 Nov 2011 04:00:00 +0100

Authors: David P King, Sara Paciga, Eve Pickering, Neal L Benowitz, Laura J Bierut, David V Conti, Jaakko Kaprio, Caryn Lerman & Peter W Park Keywords: pharmacogenetics/pharmacogenomics; addiction and substance abuse; clinical pharmacology/clinical trials; neuropharmacology; varenicline; bupropion; nicotine; smoking cessation; nicotinic receptors (Source: Neuropsychopharmacology)

Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.

Psychological Medicine — Tue, 01 Nov 2011 04:00:00 +0100

CONCLUSIONS: Although our findings require replication and functional validation, this study demonstrates the potential of GWAS to discover genes and pathways that could mediate adverse effects of antidepressant medication. PMID: 22041458 [PubMed - as supplied by publisher] (Source: Psychological Medicine)

Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals

Contemporary Clinical Trials — Fri, 28 Oct 2011 04:00:00 +0100

Abstract: Cigarette smoking is prevalent in cocaine/methamphetamine-dependent patients and associated with significant morbidity and mortality, yet, the provision of smoking cessation treatment in conjunction with substance use disorder (SUD) treatment is not standard practice. This is due, in part, to clinician concern that combining smoking cessation treatment with SUD treatment could lead to poorer SUD outcomes. The NIDA Clinical Trials Network is conducting a 10-week, two-group, randomized trial to evaluate the impact of providing smoking cessation treatment (SCT) with SUD treatment as usual (TAU), compared to TAU alone, in smokers who are in outpatient treatment for cocaine or methamphetamine dependence. Approximately 528 participants, recruited from 12 community treatment programs, w...

Bupropion No 'Magic Bullet' in Post-MI SmokersBupropion No 'Magic Bullet' in Post-MI Smokers

Medscape Today Headlines — Fri, 28 Oct 2011 02:06:16 +0100

A trial of bupropion in long-time smokers immediately post-AMI found no benefits of the drug at 1 year, suggesting that despite a 'life-changing event,' smokers struggle to kick the habit. Heartwire (Source: Medscape Today Headlines)

A Novel, Nonbinary Evaluation of Success and Failure Reveals Bupropion Efficacy Versus Methamphetamine Dependence: Reanalysis of a Multisite Trial.

CNS Neuroscience and Therapeutics — Tue, 18 Oct 2011 04:00:00 +0100

Authors: McCann DJ, Li SH Abstract A multisite, double-blind, placebo-controlled trial of bupropion for methamphetamine dependence was reanalyzed using a novel, nonbinary method of evaluating success and failure. The original analysis focused on a group response endpoint (the change in percentage of participants with methamphetamine-free urines each week over the course of the trial) and no significant bupropion effect was observed in the total population of study participants. In this reanalysis, individual participants were regarded as treatment success if they achieved multiple weeks of abstinence lasting through the end of the study, and their degree of success was quantified by calculating the number of beyond-threshold weeks of success (NOBWOS). Thus, setting the threshold at...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Effects of heart disease on depression treatment: results from the COMED study

General Hospital Psychiatry — Mon, 17 Oct 2011 04:00:00 +0100

Abstract: Objective: To determine the impact of self-reported heart disease (HD) on major depressive disorder (MDD) treatment outcomes.Method: This single-blind, 7-month prospective randomized trial enrolled 665 participants, 18–75 years old, from six primary and nine psychiatric care sites across the USA. Participants had at least moderately severe (baseline 17-item Hamilton Rating Scale of Depression ≥16), nonpsychotic chronic and/or recurrent MDD. Participants with and without self-reported HD were randomized into three treatment groups (1:1:1 ratio): escitalopram plus placebo, bupropion sustained-release plus escitalopram or venlafaxine extended-release plus mirtazapine. The primary outcome (remission) was defined by the last two consecutive 16-item Quick Inventory of Depressive Sy...

Stimulus-Induced Rhythmic, Periodic, or Ictal Discharges in a 13-Year-Old Girl After an Overdose and Respiratory Arrest

Pediatric Neurology — Sat, 15 Oct 2011 15:43:04 +0100

Paramedics found a 13-year-old, previously healthy girl with depression at home and unresponsive after overdosing on bupropion and baclofen. She was observed to be in respiratory arrest and bradycardic, with a Glasgow Coma Scale score of 3. Chest compressions were required, and she was intubated. During transport, she was hypothermic with decerebrate posturing, and manifested a 1-minute, self-terminating, generalized tonic-clonic seizure. In the pediatric intensive care unit, she received intermittent doses of lorazepam and fentanyl for sedation. She remained comatose, and continuous video-electroencephalogram monitoring was initiated to evaluate her for nonconvulsive seizures. (Source: Pediatric Neurology)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Sandoz Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 13 Oct 2011 05:00:00 +0100

Updated Date: Oct 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [PD-Rx Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 13 Oct 2011 05:00:00 +0100

Updated Date: Oct 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pilot Randomized Clinical Trial of an SSRI vs Bupropion: Effects on Suicidal Behavior, Ideation, and Mood in Major Depression

Neuropsychopharmacology — Wed, 12 Oct 2011 04:00:00 +0100

Authors: Michael F Grunebaum, Steven P Ellis, Naihua Duan, Ainsley K Burke, Maria A Oquendo & J John Mann Keywords: depression; unipolar; bipolar; psychopharmacology; clinical pharmacology; clinical trials; mood; anxiety; stress disorders; suicidal behavior; suicidal ideation (Source: Neuropsychopharmacology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Application of the conditioned taste aversion paradigm to assess discriminative stimulus properties of psychostimulants in rats

Drug and Alcohol Dependence — Sat, 08 Oct 2011 15:01:16 +0100

Conclusion: These results suggest that discriminative stimulus properties of psychostimulants can be evaluated using the CTA paradigm. (Source: Drug and Alcohol Dependence)

Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: Results from a randomized, double-blind, placebo-controlled study

Drug and Alcohol Dependence — Sat, 08 Oct 2011 15:01:12 +0100

Conclusions: Findings do not support combining nicotine patch and bupropion for smoking cessation in this population. However, findings support previous studies suggesting the importance of assessing the blind in smoking cessation studies and its possible moderating effect on medication efficacy. Future directions for enhancing smoking cessation outcome in these smokers include investigations of intensive behavioral and pharmacological interventions, including studies of potential interactions between individual genetic differences and medication efficacy. (Source: Drug and Alcohol Dependence)

BUPROPION HYDROCHLORIDEtablet, Extended Release [Eon Labs, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 07 Oct 2011 05:00:00 +0100

Updated Date: Oct 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

OBESITY: CVD Risk Cut With Rejected Weight-Loss Drug (CME/CE)

MedPage Today Pediatrics — Thu, 06 Oct 2011 17:13:09 +0100

ORLANDO (MedPage Today) -- It appears that the investigational weight-loss combination of naltrexone standard release and bupropion standard release (Contrave) reduces the predicted 10-year risk of cardiovascular events, an analysis of four phase III trials showed. (Source: MedPage Today Pediatrics)

Partial Status Epilepticus after Electroconvulsive Therapy and Medical Treatment with Bupropion

Pharmacopsychiatry — Thu, 06 Oct 2011 04:00:00 +0100

We report a patient who received right unilateral ECT under concomitant treatment with bupropion, a selective noradrenaline- and dopamine-reuptake inhibitor. After the fourth session, a focal status epilepticus occurred, which was pharmacoresistant for the duration of 12 days. We assume that the induction of a status may be facilitated by a lowering of the seizure threshold due to bupropion. An evaluation of drug therapy and control of EEG before and during ECT are recommended, especially when the drug treatment has an influence on the seizure threshold.[...]© Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Abstract | Full text (Source: Pharmacopsychiatry)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Manipulation of Cigarette Craving with Transcranial Magnetic Stimulation

Biological Psychiatry — Wed, 05 Oct 2011 03:44:42 +0100

The health risks and societal costs of cigarette smoking are well documented, but the prevalence of smoking among American adults remains high at approximately 20%. Most smokers endorse a desire to quit, but very few (only about 4–7%) will actually do so in a given year without treatment. Current commonly used treatments for tobacco dependence include nicotine replacement therapy (e.g., patch, gum, and lozenge), varenicline HCl (Chantix), bupropion HCl (Zyban), and group and/or individual psychotherapy. These treatments result in roughly 20–25% abstinence rates in smokers at 6 months or more after treatment initiation and are therefore considerably better than attempting abstinence without treatment. However, there continues to be a vital need to improve treatments for cigarette smoker...

Bupropion: Aphthous ulcers: case report

Reactions — Mon, 03 Oct 2011 06:00:13 +0100

(Source: Reactions)

Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial [Articles]

Psychiatr Serv — Mon, 03 Oct 2011 04:00:00 +0100

Conclusions: Despite differences in sociodemographic characteristics and comorbidities, when measurement-based care was used, members of different minority groups had similar outcomes when treated with one antidepressant or a combination of two antidepressants. Black participants had the highest attrition rate, an important issue to address in clinical care. (Psychiatric Services 62:1167–1179, 2011) (Source: Psychiatr Serv)

Neuropsychiatric adverse effects of centrally acting antiobesity drugs.

CNS Neuroscience and Therapeutics — Sat, 01 Oct 2011 04:00:00 +0100

Conclusion: These findings highlight the need to assess neuropsychiatric adverse events comprehensively using sensitive and validated methods early in the clinical development of candidate antiobesity drugs with a central mechanism of action. PMID: 21951371 [PubMed - in process] (Source: CNS Neuroscience and Therapeutics)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Dispensing Solutions, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 30 Sep 2011 05:00:00 +0100

Updated Date: Sep 30, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Bupropion hydrobromide propanol hemisolvate

Acta Crystallographica Section E — Fri, 30 Sep 2011 04:00:00 +0100

The title compound {systematic name: N-[1-(3-chlorophenyl)-1-oxopropan-2-yl]-tert-butanaminium bromide propanol hemisolvate}, C13H19ClNO+·Br−·0.5C3H8O, crystallizes with two independent bupropion hydrobromide ion pairs and a solvent 1-propanol molecule in the asymmetric unit. In both molecules, the expected proton transfer from HBr to the amino group of the bupropion molecule is observed, and intra- and intermolecular N—H...Br hydrogen-bond interactions are formed. These interactions link the molecules into hydrogen-bond dimers. The side chains of the two cations have slightly different orientations. The 1-propanol solvent molecule is linked to a bromide ion by an O—H...Br hydrogen bond. (Source: Acta Crystallographica Section E)

NEJM drops the ball on smoking cessation

Health Facts and Fears — Fri, 30 Sep 2011 04:00:00 +0100

A lengthy article in this week’s New England Journal of Medicine catalogues a variety of approaches to helping smokers quit within the healthcare setting, including counseling, smoking cessation medications such as bupropion and varenicline, as well as conventional nicotine replacement modalities like gum, inhalers, and patches. (Source: Health Facts and Fears)

Can’t teach an old anti-smoking drug new tricks

Health Facts and Fears — Fri, 30 Sep 2011 04:00:00 +0100

Assessment of the convulsant liability of antidepressants using zebrafish and mouse seizure models.

Epilepsy and Behaviour — Thu, 29 Sep 2011 04:00:00 +0100

Authors: Vermoesen K, Serruys AS, Loyens E, Afrikanova T, Massie A, Schallier A, Michotte Y, Crawford AD, Esguerra CV, de Witte PA, Smolders I, Clinckers R Abstract In the past, antidepressants have been thought to possess proconvulsant properties. This assumption remains controversial, however, because anticonvulsant effects have been attributed to certain antidepressants. To date, it remains unclear which antidepressants can be used for the treatment of patients with epilepsy with depression. The present study was designed to determine the anticonvulsant and/or proconvulsant effects of three antidepressants (citalopram, reboxetine, bupropion) against pilocarpine- and pentylenetetrazole-induced acute seizures in larval zebrafish and mice. In zebrafish, all antidepressants were ant...

BUPROPION HYDROCHLORIDEtablet, Film Coated [Apotex Corp]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 28 Sep 2011 05:00:00 +0100

Updated Date: Sep 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.

Experimental and Clinical Psychopharmacology — Mon, 26 Sep 2011 04:00:00 +0100

Nicotine deprivation is associated with craving, negative affect, and difficulty concentrating, which may contribute to subsequent relapse. Bupropion and varenicline are both effective treatments for smoking cessation, and evidence from clinical trials suggests that these treatments increase abstinence rates. However, the mechanism by which these medications reduce relapse remains unclear. Recent research has focused on cognitive processes, such as attention and working memory, which may predict relapse. In addition, there may also be sex differences in cognitive-related deficits during nicotine deprivation. The current sample consisted of 58 (22 females) daily smokers (at least 10 cigarettes per day) randomized to receive bupropion (300 mg/day), varenicline (2 mg/day), or placebo. After a...

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Dispensing Solutions, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 23 Sep 2011 05:00:00 +0100

Updated Date: Sep 23, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet [Dispensing Solutions, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 23 Sep 2011 05:00:00 +0100

Updated Date: Sep 23, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Diet Drugs Get a New Slim Chance at Approval

Forbes.com Healthcare News — Wed, 21 Sep 2011 21:53:43 +0100

Contrave, the investigational diet pill combination of naltrexone and bupropion, has been granted a possible new lease on life by the FDA. In January of this year the FDA issued a complete response letter to Orexigen, the drug's sponsor. Now Orexigen says that it has received guidance from the FDA that could lead to approval of the drug in 2014. (Source: Forbes.com Healthcare News)

[Interactions between metoprolol and antidepressants].

Tidsskrift for den Norske Laegeforening — Tue, 20 Sep 2011 04:00:00 +0100

Conclusion. Metoprolol should not be used concomitantly with paroxetine, fluoxetine or bupropion due to extensive interactions and the risk of serious adverse effects. Dose reductions of metoprolol should be considered for combined treatment with citalopram, escitalopram or duloxetine, while concurrent use with sertraline, venlafaxine, mianserin and mirtazapine should be safe. PMID: 21946596 [PubMed - in process] (Source: Tidsskrift for den Norske Laegeforening)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Bupropion Versus Sertraline in the Treatment of Depressive Patients with Binge Eating Disorder: Retrospective Cohort Study

Psychiatric Quarterly — Sat, 17 Sep 2011 05:48:48 +0100

This study sought to compare Bupropion versus Sertraline in the treatment of depressed patients with Binge Eating Disorder (BED) prescribed off-label. Medical records of outpatients with diagnosis of BED and Depression (DSM-IV-TR criteria) were selected: 15 patients were treated with bupropion 150 mg/per day, and 15 with sertraline 200 mg/per day. During the screening and control visits (2°–6°–14°–24° week), the selected patients were first weighed and then evaluated using the following questionnaires: Binge Eating Disorder-Clinical Interview (BEDCI), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory X (STAI-X) and Arizona Sexual Experience Scale (ASEX). Both drugs reduced anxious-depressive symptoms and binge frequency: Bupropion showed a better...

APLENZIN (Bupropion Hydrobromide) Tablet, Extended Release [Sanofi-Aventis U.S. LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 16 Sep 2011 05:00:00 +0100

Updated Date: Sep 16, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Brain energy metabolism is increased by chronic administration of bupropion

Acta Neuropsychiatrica — Fri, 16 Sep 2011 04:00:00 +0100

Conclusions: Our results demonstrated that bupropion increased some enzymes of brain energy metabolism. These findings are in accordance with other studies which showed that some antidepressants may improve energy metabolism. The present results reinforce the hypothesis that antidepressants modulate brain energy metabolism. (Source: Acta Neuropsychiatrica)

Sociodemographic and clinical factors associated with antidepressant type in a national sample of the home health care elderly

General Hospital Psychiatry — Thu, 15 Sep 2011 04:00:00 +0100

Conclusion: Race/ethnicity and age differences by AD type — including blacks' increased TCA use, Hispanics' decreased SNRI and “Other” AD use, and older elderly's increased tricyclic use — suggest systematic differences in prescribing practice variations including differences by geography, patient preferences or access to care in the HHC elderly. (Source: General Hospital Psychiatry)

BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride) Tablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 13 Sep 2011 05:00:00 +0100

Updated Date: Sep 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 08 Sep 2011 05:00:00 +0100

Updated Date: Sep 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Neonatal Exposure of Rats to Antidepressants Affects Behavioral Reactions to Novelty and Social Interactions in a Manner Analogous to Autistic Spectrum Disorders

Thu, 08 Sep 2011 04:00:00 +0100

AbstractWe have demonstrated that neonatal exposure to selective serotonin reuptake inhibitors has lasting effects on behavior and serotonergic neurons in Long Evans rats. Hyperserotoninemia and altered sensory processing are reported in autistic spectrum disorders (ASD). We hypothesized that early life exposure to SSRIs alters sensory processing, disrupts responses to novelty, and impairs social interactions in a manner similar to that observed in ASD. Male and female Long‐Evans rat pups were administered citalopram, buproprion, fluoxetine, or saline from postnatal day (P) 8–21. Rats were tested for response to a novel tone before weaning (P25). Later, rats were tested 2× for response to a novel object (P39), and to a novel conspecific (P78, P101). In addition, rats were assessed for...

Neonatal Exposure of Rats to Antidepressants Affects Behavioral Reactions to Novelty and Social Interactions in a Manner Analogous to Autistic Spectrum Disorders.

Anatomical Record — Thu, 08 Sep 2011 04:00:00 +0100

Authors: Rodriguez-Porcel F, Green D, Khatri N, Harris SS, May WL, Lin RC, Paul IA Abstract We have demonstrated that neonatal exposure to selective serotonin reuptake inhibitors has lasting effects on behavior and serotonergic neurons in Long Evans rats. Hyperserotoninemia and altered sensory processing are reported in autistic spectrum disorders (ASD). We hypothesized that early life exposure to SSRIs alters sensory processing, disrupts responses to novelty, and impairs social interactions in a manner similar to that observed in ASD. Male and female Long-Evans rat pups were administered citalopram, buproprion, fluoxetine, or saline from postnatal day (P) 8-21. Rats were tested for response to a novel tone before weaning (P25). Later, rats were tested 2× for response to a novel o...

Time-course activities of Oct1, Mrp3, and cytochrome P450s in cultures of cryopreserved rat hepatocytes.

European Journal of Pharmaceutical Sciences — Thu, 08 Sep 2011 04:00:00 +0100

Authors: Jacobsen JK, Jensen B, Skonberg C, Hansen SH, Badolo L Abstract The organic cation transporter 1 (Oct1) has been shown to be one of the most abundant uptake transporters responsible for the uptake of xenobiotics from the sinusoidal blood across the basolateral membrane of hepatocytes. On the same membrane the multidrug resistance-associated protein 3 (Mrp3) mediates the efflux of xenobiotics or their metabolites from the hepatocytes to the blood allowing their systemic exposure. In the present study we investigated the expression and activity of Oct1 and Mrp3 in suspensions and in monolayer- and sandwich cultures, and activities of CYP2B1/2, 2D1, and 3A1 in monolayer- and sandwich cultures of cryopreserved rat hepatocytes. Oct1-mediated active uptake of 10μM [(3)H]-1-meth...

Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second‐line medication strategies for treating depression?

Depression and Anxiety — Thu, 01 Sep 2011 23:00:00 +0100

Conclusions: Remission and response rates following initial antidepressant treatment failure did not differ by treatment strategy for patients with coexisting atypical symptoms or insomnia. However, some second‐step treatments for depression may be more effective than others in the presence of coexisting low energy. Subsequent prospective testing is necessary to confirm these initial findings. Depression and Anxiety 0:1–10, 2011. © 2011 Wiley‐Liss, Inc. (Source: Depression and Anxiety)

MedWorm Sponsor Message: Find the best January Sales in the UK.

ZYBAN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 01 Sep 2011 05:00:00 +0100

Updated Date: Sep 1, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 01 Sep 2011 05:00:00 +0100

Updated Date: Sep 1, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion as an Augmenting Agent in Patients of Depression with Partial Response

Basic and Clinical Pharmacology and Toxicology — Wed, 31 Aug 2011 23:00:00 +0100

In conclusion, bupropion add‐on can act as augmenting agent in patients of depression with partial response to SSRIs. (Source: Basic and Clinical Pharmacology and Toxicology)

BUPROPION HYDROCHLORIDEtablet, Film Coated [H.J. Harkins Company, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 31 Aug 2011 05:00:00 +0100

Updated Date: Aug 31, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride) Tablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 31 Aug 2011 05:00:00 +0100

Updated Date: Aug 31, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 30 Aug 2011 05:00:00 +0100

Updated Date: Aug 30, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature

General Hospital Psychiatry — Mon, 29 Aug 2011 04:00:00 +0100

Conclusions: The literature is incomplete and in some cases contradictory. In selected cases, bupropion appears to be associated with the induction of psychotic symptoms in addition to the precipitation or worsening of an existing psychotic syndrome. Further research including controlled studies is required to clarify the risk of bupropion precipitating a psychotic illness in vulnerable populations. (Source: General Hospital Psychiatry)

Bupropion: Oromandibular dyskinesia: case report

Reactions — Sat, 27 Aug 2011 15:26:04 +0100

(Source: Reactions)

A Prospective Single-arm Open-label Study of Baclofen and Bupropion SR Combination Therapy for Smoking Cessation

Addictive Disorders and Their Treatment — Fri, 26 Aug 2011 13:48:33 +0100

Conclusions: Combination of baclofen and bupropion SR seems safe and well tolerated with preliminary efficacy for smoking cessation comparing favorably with current first-line smoking cessation aids. The combination of baclofen and bupropion SR may provide an additional treatment option to varenicline or bupropion SR monotherapy. (Health Canada Clinical Trial Registration Control number: 105226). (Source: Addictive Disorders and Their Treatment)

Cost‐effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support

Addiction — Fri, 26 Aug 2011 13:46:20 +0100

Conclusions: Physician brief advice is a cost‐effective intervention and should be included in the priority list of tobacco control policy in Vietnam. Pharmacological therapies are not cost‐effective, and so they are not recommended in Vietnam at this time unless pharmaceuticals would be produced locally at substantially lower costs in the future. (Source: Addiction)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Using the Internet to Understand Smokers’ Treatment Preferences: Informing Strategies to Increase Demand

Journal of Medical Internet Research — Thu, 25 Aug 2011 23:00:00 +0100

Conclusions: Smokers accessing the Internet for information on quitting appear to differentiate cessation treatments by how much interpersonal interaction or support the treatment entails. Quitting date, smoking level, and sociodemographic variables can identify smokers with varying levels of interest in the 3 classes of cessation methods identified. These results can potentially be used to more effectively target and increase demand for these treatments among smokers searching the Internet for cessation information. (Source: Journal of Medical Internet Research)

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report

Journal of Affective Disorders — Wed, 24 Aug 2011 14:30:44 +0100

Conclusions: We found no evidence of differential remission or response rates to antidepressant combination or monotherapy between melancholic/non-melancholic MDD patients, or according to antidepressant treatment group, after 12 and 28weeks. Melancholic features may not be a valid predictor of more favorable response to antidepressant combination therapy as initial treatment. (Source: Journal of Affective Disorders)

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 19 Aug 2011 05:00:00 +0100

Updated Date: Aug 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

[Snus and cardiovascular risk.]

Annales de Cardiologie et d'Angeiologie — Tue, 16 Aug 2011 23:00:00 +0100

Authors: Underner M, Perriot J, Sosner P, Herpin D Abstract The use of "snus" (smokeless tobacco) can be detrimental to health. Snus delivers rapidly high doses of nicotine which can lead to addiction. The use of snus increases the risk of myocardial infarction and stroke. Nicotine substitution therapy as well as bupropion and varenicline reduce withdrawal symptoms and tobacco craving during snus cessation. However, they have been shown not to assist in long-term abstinence. Information concerning potential cardiovascular hazards of snus must be incorporated into health educational programs in order to discourage its use. Snus is not a recommended product to help stop smoking. PMID: 21872211 [PubMed - as supplied by publisher] (Source: Annales de Cardiologie et d'Angeiologie)

Bupropion and Restless Legs SyndromeBupropion and Restless Legs Syndrome

Medscape Today Headlines — Tue, 16 Aug 2011 11:04:50 +0100

Many antidepressants seem to exacerbate restless leg syndrome, but buproprion may prove to be an exception. Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Hyphenating the curtius rearrangement with Morita-Baylis-Hillman adducts: synthesis of biologically active acyloins and vicinal aminoalcohols

Journal of the Brazilian Chemical Society — Mon, 15 Aug 2011 22:07:23 +0100

Using Morita-Baylis-Hillman adducts as substrates, the Curtius rearrangement was performed in a sequence that allowed the synthesis of several hydroxy-ketones (acyloins) with great structural diversity and in good overall yields. These acyloins in turn were easily transformed into 1,2-anti aminoalcohols through a highly diastereoselective reductive amination step. The synthetic utility of these approaches was exemplified by performing the syntheses of (±)-bupropion, a drug used to treat the abstinence syndrome of smoker and (±)-spisulosine, a potent anti-tumoral compound originally isolated from a marine source.Um rearranjo de Curtius, utilizando adutos de Morita-Baylis-Hillman como substrato, foi realizado em uma sequência que permitiu a síntese de várias hidroxi-cetonas (aciloínas)...

---

Presse Medicale — Wed, 10 Aug 2011 23:00:00 +0100

Presse Med. 2011 Aug 11; Authors: Underner M, Perriot J, Peiffer G Abstract The use of snus (smokeless tobacco) can be detrimental to health. Containing carcinogenic nitrosamines (Swedish snus do not contain nitrosamine). Snus delivers rapidly high doses of nicotine which can lead to dependence. It do not induce bronchial carcinoma differently smoked tobacco. Lesions usually develop in the area of the mouth where the snus is placed. Non-malignant oral lesions include leukoedema, hyperkeratotic lesions of the oral mucosa and localised periodontal disease. The most frequently occurring premalignant lesion is leukoplakia. Studies reveal conflicting evidence about the risk of oral and gastroesophageal cancer with regard to snus users. However, the use of snus has proved to be a ris...

APPBUTAMONE (Bupropion Hydrochloride, Tyrosine) Kit [Physician Therapeutics LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 08 Aug 2011 05:00:00 +0100

Updated Date: Aug 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

APPBUTAMONE-D (Bupropion Hydrochloride, Tyrosine) Kit [Physician Therapeutics LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 05 Aug 2011 05:00:00 +0100

Updated Date: Aug 5, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [UDL Laboratories, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 05 Aug 2011 05:00:00 +0100

Updated Date: Aug 5, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 29 Jul 2011 05:00:00 +0100

Updated Date: Jul 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Bryant Ranch Prepack]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 29 Jul 2011 05:00:00 +0100

Updated Date: Jul 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

WELLBUTRIN (Bupropion Hydrochloride) Tablet, Film Coated [GlaxoSmithKline LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 29 Jul 2011 05:00:00 +0100

Updated Date: Jul 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion-SR for Smoking Cessation in Early Recovery from Alcohol Dependence: A Placebo-Controlled, Double-Blind Pilot Study.

The American Journal of Drug and Alcohol Abuse — Thu, 28 Jul 2011 23:00:00 +0100

Authors: Karam-Hage M, Strobbe S, Robinson JD, Brower KJ We conducted a double-blind pilot study involving 11 alcohol- and nicotine-dependent patients randomized to receive either bupropion or placebo. Four of six patients on bupropion and one of five patients on placebo were abstinent from smoking at the end of medication phase. Those in the bupropion group reported significantly less craving (p < .02) and less exposure to cigarette smoke over time (expired carbon monoxide; p < .01). There were no serious adverse events and no main effects of medication group on either per subject or total number of adverse events. All those who completed treatment remained abstinent from alcohol. PMID: 21797811 [PubMed - as supplied by publisher] (Source: The American Journal of Drug and Al...

Treatment of Apathy in Huntington’s Disease and Other Movement Disorders

Current Treatment Options in Neurology — Thu, 28 Jul 2011 15:54:04 +0100

Opinion statement Apathy is one of the most prevalent neurobehavioral symptoms in Huntington’s disease (HD), occurring in approximately 70% of the symptomatic HD population. Apathy scores in patients with HD are highly correlated with duration of illness, suggesting that apathy is an inevitable consequence of advanced disease. Although less distressing than symptoms like depression and less disruptive than irritability or aggression, apathy has a considerable adverse impact on those affected with HD because it leads to a decrease of the goal-directed behaviors that contribute much to the day-to-day quality of life. As a neuropsychiatric syndrome, apathy is also common in patients with other neuropsychiatric disorders such as Parkinson’s disease, traumatic brain injury,...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia

Pharmacoepidemiology and Drug Safety — Wed, 27 Jul 2011 23:00:00 +0100

ConclusionsOf antidepressants studied, only mirtazapine had a statistically significantly greater SD/VA risk versus paroxetine. However, baseline differences between these users suggest that this finding may be attributable to residual confounding. Eleven other antidepressants had SD/VA risks no greater than that of paroxetine, thereby providing reassurance regarding the comparative cardiovascular safety of antidepressants. Copyright © 2011 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)

BUPROPION HYDROCHLORIDEtablet, Film Coated [PD-Rx Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 26 Jul 2011 05:00:00 +0100

Updated Date: Jul 26, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Interaction of bupropion and zinc with neuronal nicotinic acetylcholine receptors.

Neuropharmacology — Mon, 25 Jul 2011 23:00:00 +0100

Authors: García-Colunga J, Godoy-García U, Vázquez-Gómez E Zinc is known to exert antidepressant-like actions and to make the effects of some antidepressants more efficient in animal models of depression. Both zinc and bupropion interact with nicotinic acetylcholine receptors (nAChRs) which are related with depression. Here we examined the effects of bupropion, in the absence and presence of zinc, on the ion current elicited by acetylcholine (ACh-current) in Xenopus oocytes expressing neuronal α4β4 nAChRs. We found that bupropion-inhibited ACh-currents depending on ACh and bupropion concentrations. Thus, the IC(50) of bupropion was lower with a higher ACh concentration: 3.51 and 2.27 μM for the current elicited with 0.5 and 2 μM ACh, respectively. The inhibitory effect of bup...

Bupropion overdose: Generalised seizure, sinus tachycardia and ST segment elevation: case report

Reactions — Sun, 24 Jul 2011 19:59:43 +0100

(Source: Reactions)

Factors associated with smoking menthol cigarettes among treatment-seeking African American light smokers.

Addictive Behaviors — Thu, 21 Jul 2011 23:00:00 +0100

CONCLUSIONS: Among AA light smokers, younger individuals and females were more likely to smoke menthol cigarettes and may be more susceptible to the health effects of smoking. Appropriately targeted health education campaigns are needed to prevent smoking uptake in this high-risk population. PMID: 21816543 [PubMed - as supplied by publisher] (Source: Addictive Behaviors)

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUPROPION HYDROCHLORIDEtablet, Film Coated [STAT RX USA LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 21 Jul 2011 05:00:00 +0100

Updated Date: Jul 21, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion: First report of acute generalised exanthematous pustulosis: case report

Reactions — Wed, 20 Jul 2011 16:58:58 +0100

(Source: Reactions)

BUPROPION HYDROCHLORIDE (Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Bryant Ranch Prepack]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 19 Jul 2011 05:00:00 +0100

Updated Date: Jul 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Varenicline increases smoking abstinence at 6 months to a year compared with placebo or bupropion; nausea is the most commonly reported adverse effect

Evidence-Based Medicine — Mon, 18 Jul 2011 23:00:00 +0100

Context Cigarette smoking is the leading cause of preventable premature death in the world, with an estimated 5 million smoking-related deaths worldwide. Quitting substantially reduces the health risk associated with smoking. Treatments available for smoking cessation include nicotine replacement therapies (NRTs), bupropion and the most recently marketed, varenicline. Varenicline, an analogue of cytisine, is a partial agonist for the α4β2 subtype of nicotinic cholinergic receptors, which are associated with the addictive effects of nicotine. Varenicline may help smokers quit smoking by reducing the rewarding effects of nicotine as well as attenuating the withdrawal symptoms.1 This meta-analysis evaluated the efficacy and safety of partial nicotine agonists, varenicline or cytisi...

Disseminated eruption of ectopic sebaceous glands following Stevens-Johnson syndrome

Journal of the American Academy of Dermatology — Sat, 16 Jul 2011 16:19:58 +0100

To the Editor: An 18-year-old white woman presented with a 1-year history of numerous asymptomatic, yellowish and skin-colored papules and plaques diffusely involving her face and chest. She reported that these lesions had developed approximately 4 months after an episode of lamotrigine-induced Stevens-Johnson syndrome (SJS). She had received only supportive care during her hospitalization for SJS; she had not received skin grafts to the face or chest. The patient was otherwise healthy except for history of a mood disorder, which was well controlled with bupropion and aripiprazole. She also periodically used eye drops (loteprednol and cyclosporine) for chronic eye irritation secondary to SJS. (Source: Journal of the American Academy of Dermatology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bupropion: Exacerbation of psoriasis and drug eruption: case report

Reactions — Wed, 13 Jul 2011 16:51:36 +0100

(Source: Reactions)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [American Health Packaging]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 07 Jul 2011 05:00:00 +0100

Updated Date: Jul 7, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion ‘safe but ineffective’ in ACS smokers

MedWire News - Cardiology — Tue, 05 Jul 2011 00:00:00 +0100

Israeli researchers report that bupropion is safe for acute coronary syndrome patients, but it is not an effective smoking cessation aid. (Source: MedWire News - Cardiology)

Life‐Threatening Bupropion Ingestion: Is There a Role for Intravenous Fat Emulsion?

Basic and Clinical Pharmacology and Toxicology — Mon, 04 Jul 2011 23:00:00 +0100

We present a 51‐year‐old woman with severe bupropion toxicity whose haemodynamic status transiently improved following intravenous fat emulsion. Serum analysis demonstrated an increase of serum concentration of hydroxybupropion, an active metabolite of bupropion, following IFE administration, lending support to one of the proposed mechanisms of IFE.Case report: A 51‐year‐old woman presented to the emergency department with generalized tonic‐clonic convulsions lasting approximately 30 sec., and a wide complex rhythm on her ECG that was suggestive of myocardial sodium channel blockade. Despite sodium bicarbonate therapy, the patient developed profound hypotension refractory to high‐dose norepinephrine. Intravenous fat emulsion (IFE) was administered with haemodynamic improveme...

Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study [Articles]

Am J Psychiatry — Thu, 30 Jun 2011 23:00:00 +0100

Conclusions: Neither medication combination outperformed monotherapy. The combination of extended-release venlafaxine plus mirtazapine may have a greater risk of adverse events. (Source: Am J Psychiatry)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Clinical Inquiry: Which smoking cessation interventions work best?

The Journal of Family Practice — Thu, 30 Jun 2011 23:00:00 +0100

Authors: Mahvan T, Namdar R, Voorhees K, Smith PC, Flake D Nicotine replacement therapy, bupropion, nortriptyline, clonidine, and varenicline are all effective, although insufficient evidence exists to recommend one intervention over another. Effective nonpharmacologic interventions include brief physician advice and more intensive counseling, such as proactive telephone counseling, group and individual counseling, and use of quit lines. PMID: 21731922 [PubMed - in process] (Source: The Journal of Family Practice)

Reversibility of impaired nasal mucociliary clearance in smokers following a smoking cessation programme

Respirology — Thu, 30 Jun 2011 00:26:40 +0100

Conclusions: A SC programme contributed to improvement in MC among smokers from the 15th day after cessation of smoking, and these beneficial effects persisted for 180 days. (Source: Respirology)

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Preferred Pharmaceuticals, Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 29 Jun 2011 05:00:00 +0100

Updated Date: Jun 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 28 Jun 2011 05:00:00 +0100

Updated Date: Jun 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Anchen Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 27 Jun 2011 05:00:00 +0100

Updated Date: Jun 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome [Original Investigation]

Archives of Internal Medicine — Sun, 26 Jun 2011 23:00:00 +0100

Conclusion In hospitalized patients with ACS who received continuous, intensive nurse counseling about smoking cessation, bupropion did not increase the rates of smoking abstinence. (Source: Archives of Internal Medicine)

Diet Drug Combination Sheds Weight in Obese Diabetic WomenDiet Drug Combination Sheds Weight in Obese Diabetic Women

Medscape Today Headlines — Fri, 24 Jun 2011 21:02:15 +0100

Combination therapy with naltrexone plus bupropion is shown to reduce body weight and glycosylated hemoglobin in overweight and obese women with type 2 diabetes. Medscape Medical News (Source: Medscape Today Headlines)

Diet drug combo sheds weight in obese diabetic women

theHeart.org — Fri, 24 Jun 2011 21:00:00 +0100

Combination therapy with naltrexone SR/bupropion SR is shown to reduce body weight and HbA1c in overweight/obese women with type 2 diabetes. For complete story visit theheart.org. (Source: theHeart.org)

WELLBUTRIN XL (Bupropion Hydrochloride) Tablet, Extended Release [Rebel Distributors Corp]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 22 Jun 2011 05:00:00 +0100

Updated Date: Jun 22, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Combination therapy with naltrexone and bupropion for obesity

Expert Opinion: Expert Opinion on Pharmacotherapy: Table of Contents — Wed, 22 Jun 2011 03:03:54 +0100

Expert Opinion on Pharmacotherapy, Volume 0, Issue 0, Page 1-14, Early Online. (Source: Expert Opinion: Expert Opinion on Pharmacotherapy: Table of Contents)

BUPROPION HYDROCHLORIDEtablet, Film Coated [Golden State Medical Supply, Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 21 Jun 2011 05:00:00 +0100

Updated Date: Jun 21, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Anchen Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 20 Jun 2011 05:00:00 +0100

Updated Date: Jun 20, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated [Golden State Medical Supply, Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Jun 2011 05:00:00 +0100

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Bryant Ranch Prepack]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Jun 2011 05:00:00 +0100

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUPROPION HYDROCHLORIDEtablet, Film Coated [Bryant Ranch Prepack]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Jun 2011 05:00:00 +0100

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUPROPION HYDROCHLORIDEtablet, Film Coated, Extended Release [Bryant Ranch Prepack]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Jun 2011 05:00:00 +0100

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Bupropion and Panic Disorder: Case Report and Review of the Literature [LETTERS TO THE EDITOR]

J Neuropsychiatry Clin Neurosci — Tue, 14 Jun 2011 23:00:00 +0100

(Source: J Neuropsychiatry Clin Neurosci)

Bupropion-Induced Mania and Hypomania: A Report of Two Cases [LETTERS TO THE EDITOR]

J Neuropsychiatry Clin Neurosci — Tue, 14 Jun 2011 23:00:00 +0100

(Source: J Neuropsychiatry Clin Neurosci)